For at least two thirds of patients aged 12 to 17 years who were treated with ustekinumab, cleared skin or minimal psoriasis was achieved at week 12 in a phase 3 study.FDA Approvals http://ift.tt/2zdmmUL
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου